BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3735805)

  • 1. Effect of injection of CCK-8 into the nucleus caudatus on the behavior of rats.
    Takeda Y; Kamiya Y; Honda K; Takano Y; Kamiya H
    Jpn J Pharmacol; 1986 Apr; 40(4):569-75. PubMed ID: 3735805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.
    Crawley JN; Stivers JA; Blumstein LK; Paul SM
    J Neurosci; 1985 Aug; 5(8):1972-83. PubMed ID: 4040554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dopaminergic and GABAergic mechanisms in discrete brain areas in phencyclidine-induced locomotor stimulation and turning behavior.
    Yamaguchi K; Nabeshima T; Kameyama T
    J Pharmacobiodyn; 1986 Dec; 9(12):975-86. PubMed ID: 3033192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sedative action of cholecystokinin octapeptide on behavioral excitation by thyrotropin releasing hormone and methamphetamine in the rat.
    Katsuura G; Itoh S
    Jpn J Physiol; 1982; 32(1):83-91. PubMed ID: 6281507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin facilitates methamphetamine-induced dopamine overflow in rat striatum and fetal ventral mesencephalic grafts.
    Wang Y; Perng SL; Lin JC; Tsao WL
    Exp Neurol; 1994 Dec; 130(2):279-87. PubMed ID: 7867757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G; Itoh S; Hsiao S
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents.
    Van Ree JM; Gaffori O; De Wied D
    Eur J Pharmacol; 1983 Sep; 93(1-2):63-78. PubMed ID: 6138272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cholecystokinin on central monoaminergic pathways.
    Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR
    Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice.
    Kovács GL; Szabó G; Penke B; Telegdy G
    Eur J Pharmacol; 1981 Jan; 69(3):313-9. PubMed ID: 6260512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
    Van Ree JM; Elands J; Király I; Wolterink G
    Eur J Pharmacol; 1989 Aug; 166(3):441-52. PubMed ID: 2572429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of unilateral intracerebroventricular microinjections of cholecystokinin (CCK) on circling behavior of rats.
    Morency MA; Ross GM; Hesketh D; Mishra RK
    Peptides; 1987; 8(6):989-95. PubMed ID: 3441450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulpiride injection into the dorsal striatum increases methamphetamine-induced gnawing in rats.
    Koshikawa N; Aoki S; Tomiyama K; Maruyama Y; Kobayashi M
    Eur J Pharmacol; 1987 Jan; 133(1):119-25. PubMed ID: 3556388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The locomotor and stereotype response to dopaminergic drugs and caffeine after intracerebroventricular kainic acid in rats.
    Kleinrok Z; Turski L; Wawrzyniak M; Cybulska R
    Pol J Pharmacol Pharm; 1981; 33(2):149-59. PubMed ID: 7198226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats.
    Jenkins OF; Jackson DM
    Neuropharmacology; 1986 Nov; 25(11):1243-9. PubMed ID: 3796797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.
    Loonam TM; Noailles PA; Yu J; Zhu JP; Angulo JA
    Life Sci; 2003 Jun; 73(6):727-39. PubMed ID: 12801594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered responding to cholecystokinins and dopaminergic agonists following 6-hydroxydopamine treatment in rats.
    Hsiao S; Katsuura G; Itoh S
    Behav Neurosci; 1985 Oct; 99(5):853-60. PubMed ID: 3939625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors.
    Fuxe K; Fredholm BB; Agnati LF; Corrodi H
    Brain Res; 1978 May; 146(2):295-311. PubMed ID: 647392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methamphetamine-induced behavioral alterations following repeated administration of methamphetamine.
    Yamanaka Y; Takano R; Egashira T
    Jpn J Pharmacol; 1986 Jun; 41(2):147-54. PubMed ID: 3091891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala.
    Belcheva I; Belcheva S; Petkov VV; Petkov VD
    Neuropharmacology; 1994 Aug; 33(8):995-1002. PubMed ID: 7845556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.